Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
RETRACTED: Protective effects of PARP inhibitor, PJ34, is related to down-regulation of calpain and NF-kappaB in a mouse model of TBI.
First author：Xiaogang Tao
Corresponding author：Baiyun Liu
essential_information
- Person in charge：Xiaogang Tao
- Data Sources： OTHERS
- Number of papers：OTHERS20190457
- Published time：2016-04-27
2016-04-27
Published articles
Journal：Brain injury
Publication type: Animal Study
IF(IF): 2.311
PMID: 27119554 Link To Pubmed Full text Download
Background And Purpose
Method
PJ34 (10 mg kg-1), a selective PARP inhibitor, was administered intraperitoneally 5 minutes and 8 hours after experimental CCI. A neurobehavioural evaluation and a histopathological analysis were then performed and the contusion volume, calpain activity and protein levels were measured in all animals.
Conclusion
PARP inhibition by PJ34 suppresses the over-activation of calpain and the production of inflammatory factors that are caused by NF-κB activation and it improves neurological functioning, decreases the contusion volume and attenuates neuronal cell death in a mouse model of CCI.
Main results
Treatment with PJ34 markedly reduced neurological deficits, decreased contusion volume and attenuated necrotic and apoptotic neuronal cell death 24 hours after CCI. The data showed that the cytosolic and nuclear fractions of calpain and NF-κB were up-regulated in the injured cortex and that these changes were reversed by PJ34. Moreover, PJ34 significantly enhanced the calpastatin and IκB levels and decreased the levels of inflammatory mediators.